

Hepatology COVID-19 Registry Week 21 Report

	Liver disease, Non-Transplant (N=47)	Post-liver transplantation (N=51)
Gender (%)	Female = 18 (38 %)	Female = 27 (52.9 %)
	Male =29 (62 %)	Male = 24 (47.1 %)
Median Age (yr) at time of COVID diagnosis (range)	10 (0.16-20)	10 (0.5-21)
Etiology of liver disease	NAFLD = 11	Biliary atresia = 19
	Biliary atresia = 12	Acute liver failure = 8
	Autoimmune hepatitis = 8	Metabolic disorders = 5
	Acute Liver Failure = 3	Tumor = 5
	Metabolic disorder = 4	Autoimmune hepatitis = 3
	Tumor = 2	Others** = 11
	Others* = 7	
Highest level of care		T
Outpatient	14	29
Hospital floor	20	18
ICU	13	4
Immunosuppression at time	No Immunosuppression = 41	Tacrolimus = 43
of COVID diagnosis	Azathioprine = 7	Steroids = 20
(*some patients were on multiple agents)	Steroids =3	Mycophenolate Mofetil = 15
		Sirolimus = 5
		Azathioprine = 3
		Everolimus = 5
0 10 - 1 10 0010		Cyclosporine = 2
Specific Treatment for COVID	Hydroxychloroquine = 7	Hydroxychloroquine = 2
(*some patients were on multiple agents)	Azithromycin = 6 IVIG = 5	Azithromycin = 2 IVIG = 1
	Remdesivir = 5	Favipiravir = 1
	Steroids = 6	Convalescent Plasma = 2
	Tocilizumab + Sarilumab = 2	Remdesivir = 1
	Eculizimab = 3	Steroid (Dexamethasone) = 1
	Convalescent Plasma = 1	Steroid (Bexamethasone) = 1
	Anakinra = 2	
Highest respiratory support		
None	36	49
Nasal cannula/CPAP/BiPAP	6	2
Mechanical ventilation	5	0
High Frequency Oscillatory ventilation	2	0
Pending information	-	-
Final clinical outcome		
Death	2***	0
Recovery	45	48
Still active in clinical course	3	3
Pending information	-	-
Liver related Complications	Ascites = 8	Infection = 1
	Portal Hypertension Bleeding =2	
	Infection = 1	


^{*}Others CLD: idiopathic cholestasis, GVHD/vanishing bile duct syndrome (Post BMT), IFALD with biliary obstruction, PFIC,PVT

** Others PLT: IFALD, Congenital hepatic fibrosis, Cryptogenic, Neonatal Hepatitis, H. Hemachromatosis,PHT,Factor V def,

***Pulmonary deterioration, multi-organ failure


Three recipients had multivisceral transplantation; One PLT recipient also had a transplanted kidney. One had SB+Liver transplant

Presenting symptoms at time of diagnosis



^{*}Constitutional symptoms reported: Loss of smell/taste , fever, myalgia, fatigue, sore throat # Other symptoms reported: Malaise, anorexia, headache, rash, Kawasaki disease like presentation(MIS-C)

Change done to Immunosuppressive agent (Post LT)



^{*}Stopped, decreased the dose, others and No changes Commonest agent **stopped**: Mycophenolate Mofetil